Effect of corticosteroid therapy on influenza-related mortality: A systematic review and meta-analysis

Journal of Infectious Diseases

Volumn 212, Issue 2, 2015, Pages 183-194

  Rodrigo, Chamira ^a   Leonardi Bee, Jo ^b   Nguyen Van Tam, Jonathan S ^b   Lim, Wei Shen ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

corticosteroid; influenza

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE; IMMUNOLOGIC FACTOR;

2009 H1N1 INFLUENZA; ARTICLE; ARTIFICIAL VENTILATION; ASTHMA; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MEGADOSE; ELECTRONIC MEDICAL RECORD; GRADING ASSESSMENT DEVELOPMENT AND EVALUATION SYSTEM; GRAFT VERSUS HOST REACTION; HEALTH CARE SYSTEM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL READMISSION; HUMAN; INFECTION RISK; INFLUENZA; INTENSIVE CARE UNIT; INVASIVE BACTERIAL INFECTION; LENGTH OF STAY; LOW DRUG DOSE; META ANALYSIS; MORTALITY; MYOCARDITIS; NEUROLOGIC DISEASE; NEWCASTLE OTTAWA SCALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERICARDITIS; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; STATISTICS; SYSTEMATIC REVIEW; TREATMENT DURATION; COMPLICATION; INFLUENZA, HUMAN; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84936877519     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu645     Document Type: Article

References (41)

1. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203-7.
2. Yu X, Zhang X, Zhao B, et al. Intensive cytokine induction in pandemic H1N1 influenza virus infection accompanied by robust production of IL-10 and IL-6. PLoS One 2011; 6: e28680.
3. Prigent H, Maxime V, Annane D. Clinical review: corticotherapy in sepsis. Crit Care 2004; 8: 122-9.
4. Kaufmann I, Briegel J, Schliephake F, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care Med 2008; 34: 344-9.
5. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids- new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.
6. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353: 1374-85.
7. Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37: 272-83.
8. Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-Analysis. Crit Care 2014; 18: R63.
9. Diaz E, Martin-Loeches I, Canadell L, et al. Group HNS-C-RW. Corticosteroid therapy in patients with primary viralpneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012; 64: 311-8.
10. Brun-Buisson C, Richard J-CM, Mercat A, Thiebaut ACM, Brochard L, Group R-SAHNvR. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183: 1200-6.
11. Linko R, Pettila V, Ruokonen E, et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand 2011; 55: 971-9.
12. Annane D, Antona M, Lehmann B, Kedzia C, Chevret S. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. Intensive Care Med 2012; 38: 29-39.
13. Farrar J. A double blind study of dexamethasone for the treatment of H5N1 avian influenza, 2006. http://www.controlled-Trials.com/ISRC TN07092892/07092892. Accessed 21 July 2014.
14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 2011. Version 5.1.0. www.cochrane-handbook.org. Accessed March 2014.
15. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction -GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94.
16. Kim S-H, Hong S-B, Yun S-C, et al. Korean Society of Critical Care Medicine HNC. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183: 1207-14.
17. Li F, Chen G, Wang J, Liu H, Wu J. A case-control study on risk factors associated with death in pregnant women with severe pandemic H1N1 infection. BMJ Open 2012; 2: e000827.
18. Liem NT, Tung CV, Hien ND, et al. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis 2009; 48: 1639-46.
19. Mady A, Ramadan OS, Yousef A, Mandourah Y, Amr AA, Kherallah M. Clinical experience with severe 2009 H1N1 influenza in the intensive care unit at King Saud Medical City, Saudi Arabia. J Infect Public Health 2012; 5: 52-6.
20. Sertogullarindan B, Ozbay B, Gunini H, et al. Clinical and prognostic features of patients with pandemic 2009 influenza a (H1N1) virus in the intensive care unit. Afr Health Sci 2011; 11: 163-70.
21. Viasus D, Pano-Pardo JR, Cordero E, et al. Novel Influenza A Study Group SNfRiID. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62: 193-9.
22. Xi X, Xu Y, Jiang L, Li A, Duan J, Du B, Chinese Critical Care Clinical Trial Group. Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality. BMC Infect Dis 2010; 10: 256.
23. Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2011; 17: 979-86.
24. Delgado-Rodriguez M, Castilla J, Godoy P, et al. Controls in Pandemic Influenza Working G. Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. J Antimicrob Chemother 2012; 67: 1739-45.
25. Wu U-I, Wang J-T, Ho Y-C, Pan S-C, Chen Y-C, Chang S-C. Factors associated with development of complications among adults with influenza: a 3-year prospective analysis. J Formos Med Assoc 2012; 111: 364-9.
26. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53: 326-33.
27. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-44.
28. Kudo K, Takasaki J, Manabe T, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One 2012; 7: e32280.
29. World Health Organization. WHO guidelines for the pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses, 2010. http://www.who.int/csr/resources/publications/swineflu/ h1n1-guidelines-pharmaceutical-mngt.pdf?ua=1. Accessed 19 June 2014.
30. World Health Organization. Clinical management of human infection with new influenza A (H1N1) virus. http://www.emro.who.int/csr/ h1n1/pdf/clinical-management-21-5-2009.pdf. Accessed 27 March 14.
31. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
32. Myles P, Nguyen-Van-Tam JS, Semple MG, et al. Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J 2013; 41: 824-31.
33. British Thoracic Society. British guideline on the management of Asthma. Thorax 2008; 63(suppl 4): iv1-121.
34. Annane D, Bellissant E, Bollaert P, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301: 2362-75.
35. Lee N, Chan PKS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492-500.
36. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50: 850-9.
37. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-Acquired pneumonia in adults: a meta-Analysis. PLoS One 2012; 7: e47926.
38. Bridges L. Extended steroid in CAP(e) (ESCAPe), 2011. http://clinicaltrials.gov/show/NCT01283009. Accessed 21 July 2014.
39. Blum C, Nigro N, Winzeler B, et al. Corticosteroid treatment for community- acquired pneumonia-The STEP trial: study protocol for a randomized controlled trial. Trials 2014; 15: 257.
40. Bos WJW. Santeon-CAP; dexamethasone in community-Acquired pneumonia, 2012. http://clinicaltrials.gov/show/NCT01743755A. Accessed 22 July 2014.
41. Ranzani OT, Ferrer M, Esperatti M, et al. Association between systemic corticosteroids and outcomes of intensive care unit-Acquired pneumonia. Crit Care Med 2012; 40: 2552-61.